Experimental group 2:Baofukang suppository, medium dose

4 trials

Sponsors

Beijing Tsinghua Changgeng Hospita, Beijing Tsinghua Changgeng Hospital

Conditions

HR-HPV16 / 18 infection with P16 positive CIN ?HR-HPV16/18 infection with CINI/P16 negative CIN II

Phase 2

A randomized, double-blind, placebo-controlled, multicenter Phase II clinical trial on the efficacy and safety of Baofukang suppository in treating HR-HPV16/18 infection with CINI/P16 negativeCIN II

RecruitingChiCTR2100043957

Beijing Tsinghua Changgeng HospitaHR-HPV16/18 infection with CINI/P16 negative CIN II

Start: 2021-03-09Updated: 2021-07-12

Efficacy and safety of Baofukang suppository in the treatment of HR-HPV16 / 18 infection with P16 positive CIN II: a randomized, double-blind, placebo-controlled, multicenter phase II clinical trial

Active, not recruitingChiCTR2100043958

Beijing Tsinghua Changgeng HospitalHR-HPV16 / 18 infection with P16 positive CIN ?

Start: 2021-03-09Updated: 2021-07-12

Efficacy and safety of Baofukang suppository in the treatment of HR-HPV16 / 18 infection with P16 positive CIN II: a randomized, double-blind, placebo-controlled, multicenter phase II clinical trial

Active, not recruitingITMCTR2100004529

Beijing Tsinghua Changgeng HospitalHR-HPV16 / 18 infection with P16 positive CIN ?

Start: 2021-03-09Updated: 2023-02-20

A randomized, double-blind, placebo-controlled, multicenter Phase II clinical trial on the efficacy and safety of Baofukang suppository in treating HR-HPV16/18 infection with CINI/P16 negativeCIN II

RecruitingITMCTR2100004528

Beijing Tsinghua Changgeng HospitaHR-HPV16/18 infection with CINI/P16 negative CIN II

Start: 2021-03-09Updated: 2023-02-20